Pure Global AI
NCT06379412Recruiting

A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Colorectal Cancer

Zhujiang HospitalClinicalTrials.govother
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
observational study, no intervention
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Zhujiang Hospital
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2023
End date
Dec 01, 2024
Enrollment
200 participants
Primary outcome

HPLC-MS/MS was used to detect peptidoglycan fragment content in biological specimens of 200 participants

Summary

The goal of this observational study is to explore the association of peptidoglycan fragments
 derived from gut microbiota with colorectal cancer (CRC). The main question it aims to answer
 is: Are peptidoglycan fragments from the gut microbiota associated with the progression of
 colorectal cancer? Participants will provide biological specimens (blood, feces, colon tissue
 obtained during surgery)

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06379412
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06379412 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhujiang Hospital and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.